3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
94
Prostatic Neoplasms, Castration-Resistant
10
Neoplasm Metastasis
8
Breast Neoplasms
8
Neoplasms
7
Triple Negative Breast Neoplasms
4
Metastatic Castration-Resistant Prostate Cancer
4
Carcinoma, Non-Small-Cell Lung
4
Small Cell Lung Carcinoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Melanoma
3
Colorectal Neoplasms
3
Carcinoma, Hepatocellular
3
Bulbo-Spinal Atrophy, X-Linked
3
Adenocarcinoma
3
mCRPC
2
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Prostate Adenocarcinoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Hormone Sensitive Prostate Cancer
2
Metastatic Castration-resistant Prostate Cancer
2
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2
Bites and Stings
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Interventions
fludarabine
19
Whole-Body Irradiation
18
Cyclophosphamide
17
fludarabine phosphate
16
ruxolitinib
15
Mycophenolic Acid
14
Specimen Handling
13
Tacrolimus
11
Azacitidine
11
Biopsy
10
Peripheral Blood Stem Cell Transplantation
9
Melphalan
9
Cytarabine
9
venetoclax
8
Sirolimus
8
Busulfan
8
Stem Cell Transplantation
6
Injections
6
Granulocyte Colony-Stimulating Factor
6
Daunorubicin
5
Cyclosporine
5
CPX-351
5
luspatercept
4
ivosidenib
4
itacitinib
4
fedratinib
4
decitabine and cedazuridine drug combination
4
Thiotepa
4
Liposomes
4
Cyclosporins
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
enzalutamide
×
1 year
×
Clear all
No trials found.